3Wolfe GI, Kaminski HJ ,Jaretzki A Ⅲ, et al. Development of a thymectomy trial in nonthymomatous myasthenia gravls patients receiving immunosuppressive therapy. Ann NY Acad Sci ,2003,998:473 － 480.
4Jaretzki A Ⅲ,Aarti JA, Kaminski HJ ,et al. Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. Ann Thorac Surg,2003 ,76 :1 － 3.
5Richman DP,Agius MA. Treatment principles in the management of autoimmune myasthenia gravis. Ann NY Acad Sci ,2003,998:457 － 472.
6Keesey JC. Clinical evaluation and management of myasthenia gravis.Muscle Nerve.2004.29:484 － 505.
7Kupersmith MJ, Latkeny B, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Nenrol,2003,60:243 － 248.
8Monsul NT,Patwa HS,Knorr AM,et al. The effect of prednisone on the progression from ocular to generalized myasthenia gravis. J Neurol Sci,2004,217:131 － 133.
9Mee J, Paine M, Byrne E, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neurooph-thalmol.2003 .23 :251 － 255.
10American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum,2001.44 : 1496 － 1503.
